Trial
NCT05377827
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Washington University School of Medicine
Collaborators
Wugen, Inc.
Condition
T-Cell Non-Hodgkin Lymphoma
Intervention
WU-CART-007
Why stopped
Drugs/Equipment Unavailable
Provenance
Dataset: 2026-07-24 • Source: ClinicalTrials.gov API v2 • Last update: 2026-07-21